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http://dx.doi.org/10.1016/j.ccr.2013.08.009SUMMARYProteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain controversial. We report
the existence of a progenitor organization in primary MM that recapitulates maturation stages between
B cells and plasma cells and that contributes to clinical PI resistance. Xbp1s tumor B cells and pre-plasma-
blasts survive therapeutic PI, preventing cure, while maturation arrest of MM before the plasmablast stage
enables progressive disease on PI treatment. Mechanistically, suppression of Xbp1s in MM is shown to
induce bortezomib resistance via de-commitment to plasma cell maturation and immunoglobulin production,
diminishing endoplasmic reticulum (ER) front-loading and cytotoxic susceptibility to PI-induced inhibition of
ER-associated degradation. These results reveal the tumor progenitor structure inMMand highlight its role in
therapeutic failure.INTRODUCTION
Multiple myeloma (MM) is a late-stage lymphoid malignancy
characterized by the accumulation of immunoglobulin (Ig)-
secreting plasma cells within the bone marrow. Existing
therapies for MM, including the proteasome inhibitors (PIs)
bortezomib (BTZ) and carfilzomib, can extend survival but are
not curative (Alexanian et al., 2012; Richardson et al., 2005). To
understand the failure to cure, drug resistance mechanisms
must be characterized. Although the binding target of PIs has
been recognized since their inception, the mechanisms of PI
cytotoxicity and resistance in MM remain controversial. While
some studies have linked PI cytotoxicity to stabilization of tumor
suppressors (such as p53), pro-apoptotic proteins (such as
Noxa, Bim, and Bik), or inhibitors of anti-apoptotic proteins
(such as NF-kB; Chen et al., 2010; McConkey and Zhu, 2008),
others have identified induction of endoplasmic reticulum (ER)Significance
PIs, including bortezomib, are a mainstay of treatment for MM
anisms have not been validated in the clinic and reflect an artif
described here that occurs in patients with MM; because this
confirmation of in vitro drug resistance models is highlighted.
which contributes to therapeutic resistance, suggesting that
an extensive progenitor organization is revealed in primary MM
gies must better address early MM progenitors.
Castress as the critical mediator of antitumor activity (Lee et al.,
2003; Obeng et al., 2006).
Whereas each of the pleiotropic effects of PIs may cause
cellular cytotoxicity in a specific context, induction of ER stress
likely accounts for the unique sensitivity of MM to PIs in the clinic
(Kim et al., 2008; Lee et al., 2003; Obeng et al., 2006). In plasma
cells, the ER is expanded to accommodate the synthesis of
secretory Ig. Physiologic ER stress, which can be very heavy in
professional secretory cells, is counteracted via adaptations
known collectively as the unfolded protein response (UPR).
Three ER resident transmembrane proteins (Ire1, Perk, and
Atf6) activate overlapping components of the UPR, which coun-
ters unfolded protein stress by suppressing global mRNA
translation while selectively upregulating pathways that promote
protein folding or degradation (Ron and Walter, 2007). PIs
impede ER homeostasis by inhibiting proteasome-assisted
ER-associated degradation (ERAD; Kim et al., 2008), causingbut fail to cure. Previously reported in vitro resistance mech-
act of cell culture. An alternative PI resistance mechanism is
differs from in vitro resistance reports, the need for clinical
Our results reveal that MM cells tolerate XBP1 inactivation,
IRE1 inhibitors may prove ineffectual in MM. Furthermore,
. Our results suggest that to achieve cure, treatment strate-
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Figure 1. Loss of Ire1 or Xbp1 Reduces the Cytotoxic Activity of BTZ in MM
(A and B) Synthetic lethal BTZ-siRNA screens of the kinome (A) and ‘‘druggable’’ genome (B), conducted in KMS11MMcells, showing genes ranked by the mean
Bliss independence score of siRNA at BTZ IC90. Synthetic lethal geneswhose RNAi caused greater than additive cytoxicity (in red) with BTZ are to the left; rescue
genes whose RNAi reduced BTZ cytotoxcity (in blue) are to the right. IRE1 ranking is shown.
(C) Viability (MTT assay) of MM cell lines expressing shIRE1 or shXBP1 for the indicated time following lentiviral (LV) infection. Controls included uninfected cells
and cells expressing nontargeted (NT) shRNA.
(legend continued on next page)
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istically inactivate Eif2a, increase Atf4, and upregulate the
expression of UPR genes such as CHOP (DDIT3) and HSPA5
(Chen et al., 2010; Lee et al., 2003; Obeng et al., 2006; Zhu
et al., 2010).
The mechanisms by which tumor cells escape the multiple
cytotoxic effects of PIs are not implicit. One compelling possibil-
ity is that proteasome inhibition is prevented by mutation of the
PI-binding site. Indeed, mutations of the BTZ-binding site on
proteasome subunit b5 (PSMB5) or overexpression of PSMB5
have been observed in various tumor cell lines and have been
asserted to be the mechanism of PI resistance in both MM and
leukemia (Balsas et al., 2012; de Wilt et al., 2012; Franke et al.,
2011; Oerlemans et al., 2008; Ru¨ckrich et al., 2009). Notably,
however, BTZ resistance in these studies was developed
in vitro, using cell lines adapted to PI exposure, and the legiti-
macy of these models for the representation of drug resistance
in patients remains unverified. To the contrary, multiple
sequencing studies of primary MM tumors have failed to identify
any proteasome mutations to account for PI resistance
(Chapman et al., 2011; Lichter et al., 2012; Politou et al., 2006;
Wang et al., 2008), suggesting that such mutations, although
capable of mediating PI resistance in vitro, are infrequent in the
clinic. In this study, we sought to define mechanisms of PI resis-
tance in patients with MM.
RESULTS
Ire1-Xbp1 Signaling Is Dispensable for MM Tumor Cell
Viability but Required for BTZ-Induced Cytotoxicity
In Vitro
We have previously conducted kinome- and genome-scale
siRNA studies in the KMS11 MM cell line treated with BTZ to
functionally identify synthetic lethal chemosensitizing targets
(Tiedemann et al., 2010, 2012; Zhu et al., 2011). We re-analyzed
these results to identify genes whose silencing protected MM
cells from BTZ-induced cytotoxicity (Figures 1A and 1B). While
relatively few BTZ-rescue genes were detected, ‘‘endoplasmic
reticulum to nucleus signalling 1’’ (ERN1), better known as
IRE1, appeared critical for BTZ response in both studies. On
kinome screening, IRE1 was the kinase whose loss was most
associated with BTZ resistance, whereas in genome-scale
siRNA studies, IRE1 ranked at the top 1% of genes required
for BTZ-induced cell death.
Identification of IRE1 in this context was surprising because
Ire1 knockdown prevents activation of one branch of the homeo-
static UPR pathway, and accordingly its loss might be predicted
to diminish a cell’s ability to respond to ER stress—rendering it
more sensitive to BTZ—contrary to our observation. Therefore,
to verify this result and to explore whether Ire1 suppression in-
duces BTZ resistance in other MM subtypes, Ire1 was silenced(D) Viability (MTT) of MM cell lines infected with LV to express shIRE1 or shXBP1 f
concentration (4–7.5 nM) for 3 days.
(E) Western blot of Ire1 levels in shIRE1-treated and control NT shRNA-treated M
(F) RT-PCR analysis of XBP1 mRNA in shXBP1-treated and control MM cells. u,
(G) Viability of OCI-MY5 MM cells treated with UPR gene shRNA, following cultu
Error bars represent ± SEM (n = 3).
See also Figure S1.
Cain six other MM cell lines (Figures 1C and 1E); cells were then
grown in the presence or absence of BTZ. In the absence of
drug, loss of Ire1 was well tolerated (Figure 1C), albeit that mild
reductions in proliferation were observed for RPMI-8226 and
JJN3 cells. Conspicuously, however, suppression of Ire1 (Fig-
ure 1E) induced relative BTZ resistance in all MM lines tested
(Figure 1D; Figures S1A–S1D available online), confirming our
initial observation.
Ire1 activates the UPR via the bZIP transcription factor, Xbp1.
When stimulated by ER stress, Ire1 splices 25 nucleotides from
the unspliced XBP1 mRNA (XBP1u) to yield a frame-shifted
mRNA (XBP1s) that encodes the active transcription factor (Cal-
fon et al., 2002). Because XBP1 was not tested in our original
siRNA studies, its effect on BTZ response was assessed next.
Surprisingly, silencing of XBP1 (Figure 1F), like IRE1, was well
tolerated inMMcells (Figure1C) evenunder conditionsof extreme
hypoxia (Figure 1G), contrary to previous reports that XBP1 is
required for myeloma pathogenesis (Carrasco et al., 2007). Strik-
ingly, however, loss of Xbp1 induced BTZ resistance in all six MM
cell lines tested, mirroring Ire1 suppression (Figure 1D). Similar
results were obtained with four distinct shRNA. Therefore, the
Ire1-Xbp1 pathway is dispensable for MM cell viability but pro-
motes BTZ cytotoxicity, at least in MM cell lines grown in vitro.
Ire1-Xbp1 Signaling Is Suppressed in BTZ-Refractory
Primary MM
To determine if attenuation of Ire1-Xbp1 signaling occurs in pri-
mary MM and plays a role in BTZ resistance, we next examined
the gene expression of pretreatment tumor samples from
patients with MM in whom either a complete response (CR) or
progressive disease (PD) developedwith single-agent BTZ treat-
ment (Mulligan et al., 2007; Richardson et al., 2005). Conspicu-
ously, almost all Xbp1 target genes (Shaffer et al., 2006) were
expressed at lower levels in PD tumors (Figure 2A), concordant
with our observation that Ire1-Xbp1 signaling modulates BTZ
sensitivity in MM cell lines. However, the difference in Xbp1-
target gene expression between BTZ CR and PD primary MM
tumors was modest, suggesting that, pretreatment, Xbp1s
activity may be suppressed in only a subpopulation of cells in
BTZ-refractory tumors.
Notably, from a library of lymphoid transcription factor signa-
tures, only Xbp1 correlated closely with clinical BTZ response.
In comparison, no association was observed between BTZ
response and tumor expression of p53, NF-kB, or Stat3 (Fig-
ure 2B). Similarly, no positive association was observed between
BTZ resistance and proteasome expression in primary MM;
instead, most proteasome subunits including PSMB5 are down-
regulated in BTZ-resistant MM (Figure S2), contrary to in vitro
resistance models.
The preferential expression of Xbp1 target genes in BTZ-
sensitive MM tumors, relative to BTZ-resistant tumors, wasor 1 day and then treated with vehicle or BTZ at an approximate 75% inhibitory
M cells.
unspliced; s, spliced.
re in normoxia (20.95% O2) or extreme hypoxia (0.2% O2).
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independent Xbp1 gene signatures, derived by distinct methods.
Whereas an Xbp1 signature derived from overexpression of
Xbp1 in B cells (Shaffer et al., 2004) was moderately enriched
in BTZ-sensitive primary MM tumors (q = 0.07; Figure 2C), a
second Xbp1 signature representing genes with Xbp1-binding
promoters, was significantly enriched (q = 0.026; Figure 2D). A
third Xbp1 signature, derived from profiling of MM cells following
Xbp1 knockdown, most closely matched the biological context
in which Xbp1 activity was being assessed and showed the
most significant enrichment in BTZ-sensitive MM (q = 0.024;
Figure 2E). In addition, a fourth related Ire1 gene signature,
derived from MM cells with Ire1 knockdown, was also enriched
in BTZ-sensitive primary MM (q = 0.048; Figure 2E), consistent
with the requirement for Ire1 activation of Xbp1. Thus, GSEA of
primary MM tumors from patients treated with single-agent
BTZ confirm that downregulation of the Ire1-Xbp1 pathway
occurs in primary myeloma and correlates with therapeutic PI
resistance.
XBP1 Mutations in MM
Suppression of Xbp1 signaling may occur through a variety of
mechanisms, including XBP1 gene mutation. Notably, while
genome sequencing of 20 treated MM tumors did not identify
any proteasome PSMB5 mutations, this initial genomic analysis
ofMMdid identify twomutations in XBP1 (Chapman et al., 2011),
both in treatment-refractory tumors (Figure 2F). Conspicuously,
the first mutation, XBP1-L167I, maps to the Ire1 splice site on
XBP1u and, we predicted, might prevent splice activation to
XBP1s (Figure 2G). The second mutation, XBP1s-P326R,
involves a nonconservative missense mutation within the
trans-activation domain of Xbp1s, where loss of proline’s confor-
mational rigidity may affect tertiary structure and influence
transcriptional activity.
To confirm if either or both of these mutations are inactivating,
identical XBP1 mutants were generated and expressed in MM
cell lines (Figures 2H and 2I); simultaneously endogenous
XBP1 was silenced using a 30UTR-targeted shXBP1. As pre-
dicted, the mutation, XBP1-L167I, consistently prevented
splicing of XBP1u mRNA to XBP1s, whereas unmutated
XBP1u mRNA, expressed in parallel, could be processed. WhileFigure 2. Ire1-Xbp1 Signaling Is Suppressed or Mutated in BTZ-Refrac
(A) Comparative gene expression of BTZ-responsive and -resistant primary MM f
plotted by rank-order of differential mean expression in tumors that responded co
The vertical axis shows the log ratio of mean tumor expression intensity in the tw
(B) Heatmaps comparing the relative expression of an Xbp1 gene signature with
BTZ-resistant (PD) primary MM tumors, using the same probe set rank-order as i
signature probe sets per 1,000 rank-ordered probe sets. The suffixes up, down
transcription factor signatures.
(C–E) Gene set enrichment analysis (GSEA) for Xbp1 target genes in primary MM,
BTZ-refractory tumors. Four distinct Xbp1 signatures were used, derived either b
binding motifs within their promoters (D), or by shRNA knockdown of either Xbp
(F) XBP1 mutations identified on initial genome sequencing of 38 patient MM
BTZ, dexamethasone.
(G) Thewild-type (left) and L167Imutation (right, indicated by the red letter) XBP1u
hairpin.
(H) RT-PCR analysis of XBP1u and XBP1s mRNA in three MM cell lines engineere
tumors. Endogenous XBP1 mRNA was suppressed using a 30UTR-targeted shX
(I) Relative viability (MTT) of the MM cell lines in (H) following treatment with BTZ
See also Figure S2.
Caboth XBP1u and XBP1s are translated, only Xbp1s protein is
transcriptionally active; Xbp1u, which has a functional N-termi-
nal leucine zipper motif, instead acts as an inhibitor of Xbp1s
(Lee et al., 2003). L167I therefore inhibits XBP1 both by
decreasing Xbp1s and by increasing Xbp1u.
We next assessedwhether these XBP1mutations have effects
on drug response by testing the mutant XBP1 cell lines for BTZ
sensitivity (Figure 2I). Consistent with our earlier observations,
knockdown of endogenous Xbp1 in OCI-MY5, JJN3, or
SKMM2 control cells, using an XBP1 30UTR-directed shRNA,
attenuated BTZ cytotoxicity. Constitutive expression of an
shRNA-resistant XBP1s CDS, however, re-established sensi-
tivity to BTZ, despite endogenous XBP1 silencing, verifying
that BTZ sensitivity in MM cells is modulated specifically
by Xbp1s. In contrast, constitutive expression of the mutant
XBP1s-P326R or XBP1u-L167I CDS in MM cells failed to resen-
sitize shXBP1-treated MM cells to BTZ, indicating that both
mutations are functionally inactivating and promote BTZ resis-
tance. These studies indicate that primary MM tumors tolerate
inactivating mutations in XBP1 and that PI therapy may exert a
selective pressure for the emergence of cells with suppression
of this pathway.
Of UPR Stress Transducers, Only Ire1-Xbp1, and Not
Atf6 or Perk, Regulates BTZ Sensitivity
Ire1 is one of three ER transmembrane proteins that transduce
stress signals to the nucleus to induce the UPR. To determine
if loss of either of the other ER stress transducers, Perk or Atf6,
induced BTZ resistance, each transducer was knocked down
separately using two shRNA in RPMI-8226 and SKMM2 MM
cells (Figure 3A). However, suppression of Atf6 or Perk, unlike
suppression of Ire1-Xbp1, had no effect on BTZ sensitivity (Fig-
ures 3B, 3C, and S3), indicating that among the ER stress path-
ways, BTZ sensitivity maps specifically to Ire1-Xbp1.
BTZResistance Is Not Due to Increases in Perk or Atf6 or
Loss of an Xbp1s Death Signal
Whereas BTZ cytotoxicity inMMhas been linked to the induction
of overwhelming ER stress, we show here that loss of the Ire1-
Xbp1 branch of the ER homeostasis apparatus reduces BTZ
lethality, contrary to expectation. To address this dilemma, andtory Primary Tumors from MM Patients
rom patients enrolled on the APEX 039 clinical study. Affymetrix probe sets are
mpletely (CR) or that showed progressive disease (PD) following BTZ therapy.
o response groups. Xbp1s target genes are identified above the plot.
that of other B cell transcription factor signatures in BTZ-sensitive (CR) versus
n (A). To normalize for signature sizes, results are plotted as the percentage of
, repressed, and 23 reflect the selection criteria used to define genes in the
among genes preferentially expressed pretreatment in BTZ-responsive versus
y overexpression of Xbp1 in B cells (C), by identification of genes with Xbp1-
1 or Ire1 in MM cells (E). NES, normalized enrichment score.
, and subsequent patient treatment response. CyBorD, cyclophosphamide;
mRNA sequences at the Ire1 splice site (indicated by the black arrow on the left)
d to express mutant XBP1 CDSs recapitulating mutations identified in primary
BP1.
or vehicle for 3 days (mean ± SEM).
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Figure 3. Only Ire1 among ER Stress Trans-
ducers Regulates BTZ Sensitivity in MM
(A) Immunoblot of indicated proteins in RPMI-8226
MM cells 1.5 days after LV infection to express
shIRE1, shATF6, shPERK, or control NT shRNA. In
the ATF6 panel, irrelevant lanes were removed
between NT shRNA and shATF6 lanes for all four
blots; all samples were run on the same gel.
(B) Growth of MM cell lines expressing shIRE1,
shATF6, shPERK, or control NT shRNA measured
by sequential MTT assays 24 and 96 hr after LV
infection.
(C) Viability (MTT assay) of MM cell lines infected
with LV for 24 hr to express shIRE, shATF6, or
shPERK and then treated with BTZ at IC90 or
vehicle for 3 days.
Error bars show ± SEM. See also Figure S3.
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loss of Ire1-Xbp1 signaling in MM cells might cause a compen-
satory increase in Atf6 or Perk signaling (and in downstream
UPR gene expression) that might ‘‘pre-adapt’’ MM cells to better
withstand proteasome inhibition. To investigate this possibility,
we generated MM cells in which both Ire1 and Atf6, or both
Ire1 and Perk, were concurrently suppressed (Figures 4A and
4B). Notably, double knockdown of Ire1 and Perk, or of Ire1
and Atf6 together, in MM cells, failed to diminish the induction
of BTZ resistance by Ire1 silencing (Figures 4C and 4D), indi-
cating that neither of these parallel pathways individually medi-
ates the BTZ resistance seen on Ire1 suppression. Conceivably,
however, Ire1-Xbp1 suppression might cause compensatory in-
creases in both Atf6 and Perk, either of which might then redun-
dantly prime cells to survive proteasome inhibition. Therefore, to
test this hypothesis, we also generated triple knockdown MM
cells in which Ire1, Atf6, and Perk were all concurrently sup-
pressed (Figure 4E). Surprisingly, these cells proved viable in tis-
sue culture, although they demonstrated a growth disadvantage
(Figure 4F). Notably, however, simultaneous silencing of both
Atf6 and Perk failed to diminish BTZ resistance induced on Ire1
silencing (Figure 4G). Therefore, BTZ resistance arising from
Ire1-Xbp1 loss is not mediated via parallel UPR pathways.
We next speculated that the overwhelming ER stress gener-
ated by PI therapy might induce a lethal signal transmitted via
Ire1-Xbp1 and that loss of this death signal might underlie BTZ294 Cancer Cell 24, 289–304, September 9, 2013 ª2013 Elsevier Inc.resistance. However, MM cells forced to
constitutively overexpress Xbp1s protein,
the final common effector of Ire1-Xbp1
signaling, remain viable in vitro (Figures
4H, 4I, and S4) and in vivo (Carrasco
et al., 2007), providing no evidence for
the existence of an Xbp1s death signal
in these cells.
Ire1-Xbp1 Suppression in MM
Blocks Commitment to Plasma Cell
Differentiation and Lowers ER
Stress
XBP1 is essential for differentiation of
B lymphocytes to plasma cells, particu-larly for the terminal maturation of proliferating plasmablasts
to plasma cells, for induction of Ig secretion, and for bone
marrow colonization (Carrasco et al., 2007; Hu et al., 2009;
Reimold et al., 2001). Because the role of Ire1-Xbp1 signaling
in BTZ resistance remained unaccounted for, we next sur-
mised that loss of Ire1-Xbp1 signaling might cause de-
commitment of MM cells to terminal plasma cell differentiation
and that tumor cell immaturity might account for cellular BTZ
resistance.
To investigate this possibility, we first assessed MM cell lines
for evidence of reversion of plasma cell commitment following
RNAi-induced silencing of IRE1 or XBP1. Following knockdown
of Ire1 or Xbp1, OCI-MY5 cells appeared smaller and rounder
with less cytoplasm and perinuclear hof (Figure 5A), resembling
pre-plasmablasts (Jourdan et al., 2011). Profiling of gene expres-
sion in IRE1- or XBP1-silenced MM cell lines demonstrated
partial repression of markers of plasma cell maturation such as
SDC1 (CD138), CD38, IL6R, and IL6ST in these cells and simul-
taneous weakmRNA expression of B cell markers such asCD20
and PAX5 (Figure 5B). Diminished expression of CD138 ± CD38
surface antigens on XBP1-silenced RPMI-8226 and JJN3 MM
cells was confirmed by flow cytometry (Figure 5C), while upregu-
lation of Pax5 protein in Ire1-Xbp1 inactivated MM cells was
confirmed by immunoblot (Figure 5D). Because Pax5 is ex-
pressed in B cells but is suppressed in plasma cells (Nutt
et al., 2011), these findings are consistent with the hypothesis
Figure 4. BTZ Resistance Induced by Ire1-Xbp1 Suppression Is Not Due to Adaptive Increases in Perk or Atf6
(A) Immunoblot of Ire1, Atf6, and Perk in JJN3 MM cells expressing concurrently shIRE1 and shATF6, 2 days postinfection. Control cells expressed NT shRNA.
(B) Same as (A) except that MM cells concurrently expressed shIRE1 and shPERK.
(C) Growth of JJN3MM cells following knockdown of Ire1, or dual knockdowns of Ire1+Atf6 or Ire1+Perk, measured by sequential MTT assays 1 and 4 days after
infection.
(D) Viability (MTT) of JJN3 MM cells infected with indicated LV shRNA combinations for 1 day and then treated with BTZ or vehicle for 3 days.
(E) Immunoblot of indicated proteins in JJN3MMcells infectedwith LV to concurrently express shRNA targeting all three ERUPR transducers Ire1, Atf6, and Perk.
Control cells expressed NT shRNA.
(F) Growth of JJN3 MM cells following triple knockdown of Ire1+Atf6+Perk, compared with single or dual gene knockdowns, measured by MTT assays 1 and
4 days after LV infection.
(G) Same as (D) but includes JJN3 MM cells with simultaneous triple knockdown of Ire1, Atf6, and Perk.
(H) Immunofluorescence staining for Xbp1s in OCI-MY5 MM stably overexpressing XBP1u or XBP1s CDS. Nuclei are stained with DAPI. Scale is identical for all
micrographs.
(I) Growth of OCI-MY5 cells overexpressing XBP1u or XBP1s, compared with control cells infected with empty expression vector, measured by repeat MTT
assays at 0 and 3 days.
Error bars represent ± SEM. See also Figure S4.
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Figure 5. Ire1-Xbp1 Suppression and BTZ Resistance in MM Are Associated with De-Commitment to Plasma Cell Differentiation
(A) Giemsa stain of OCI-MY5 cells following expression of NT shRNA, shIRE1, or shXBP1. Scale is identical for all micrographs.
(B) Relative mRNA abundance of indicated genes in JJN3 and RPMI-8226 MM cell lines expressing shIRE1, shXBP1, or control NT shRNA.
(C) Flow cytometric analysis of surface CD38 and CD138 on JJN3 and RPMI-8226 MM cell lines expressing shXBP1 or control NT shRNA.
(D) Immunoblot analysis of indicated proteins in JJN3, OCI-MY5, and RPMI-8226 MM cell lines 3 days after LV infection to express shIRE1. Proteins were
separated on either 7.5% (*) or 15% (**) polyacrylamide gels. IgL reflects k for JJN3 and l for RPMI-8226 and OCI-MY5.
(E) Immunoblot of Ddit4 induction by BTZ (100 nM, 6 hr) in JJN3 and RPMI-8226 MM cells expressing either shIRE1 or control shRNA.
(F) Relative expression of indicated B cell and plasma cell maturation genes among primary MM that respond (with CR) or fail to respond (with PD) to clinical BTZ
treatment. Data are from pre-BTZ samples from patients treated on the APEX 039 study.
(G) Box-whisker plots of relative expression of indicated genes from (E) during physiological B cell to plasma cell maturation, with median shown in red.
See also Figure S5 and Table S1.
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plasma cell maturation.
We next assessed Ig production in Xbp1s-silenced MM
cells. By gene expression profiling, loss of Xbp1 or Ire1 was
associated with decreased expression of both IgG heavy
chain (IGHG) and Igk-light chain (IGK), in IgGk-secreting JJN3
cells, as well as decreased expression of IL21R, a regulator
of IgG production (Ozaki et al., 2002; Figure 5B). A marked
decline in Ig light chain protein production in Ire1-Xbp1s
silenced MM cells was also observed by immunoblot (Fig-
ure 5D). XBP1 is a known prerequisite for establishing Ig
production by B cells (Reimold et al., 2001), and our data indi-
cate that MM plasma cells remain dependent on Xbp1s for
ongoing Ig synthesis.
We next hypothesized that by arresting or reversing their
secretory plasma cell maturation, MM tumor cells may lessen
their ER front loading by secretory Ig and thereby diminish
both their basal ER stress and their risk of lethal ER stress
arising from PI-induced ERAD inhibition, providing a mecha-
nism by which Xbp1s loss (and other forms of maturation
arrest) might cause PI resistance. Consistent with this, MM
cell lines in which IRE1 or XBP1 were silenced showed reduced
expression of UPR genes such as ATF4, DDIT3 (CHOP), DDIT4
(REDD1), PPP1R15A (GADD34), and HSPA5 (BiP); and of
downstream chaperones HSP90B1 and DNAJB9 (Figure 5B).
Notably, this diminished expression of UPR genes in Ire1-
Xbp1s inactivated MM cells reflected reduced ER stress rather
than simple loss of Xbp1s-driven gene transcription because
Ire1-Xbp1s silencing was accompanied by reduced or stable
expression of genes in parallel ER stress pathways such as
EIF2AK3 (PERK), ATF4, and PPP1R15A (GADD34; Figures 5B
and 5D). If loss of Xbp1s-driven gene expression alone
accounted for the decline in CHOP and chaperones, without
a concurrent decrease in ER stress, these parallel UPR homeo-
stasis pathways would instead be activated as they assumed
the burden of ER homeostasis. A significant decline in basal
expression of Perk-responsive UPR elements Atf4, Gadd34,
and Chop in shIRE1-treated MM cells was confirmed by immu-
noblot (Figures 5D, S5A, and S5B). Furthermore, suppression
of Ire1 caused diminished induction of the Atf4 response
gene DDIT4 (REDD1) following either BTZ- or thapsigargin-
induced ER stress (Figures 5E and S5C). Because Ire1-Xbp1s
suppression causes de-commitment to Ig production and a
decline in ER stress, whereas PI cytotoxicity in MM has been
linked to exacerbation of ER stress, which in plasma cells is
driven by Ig production (Obeng et al., 2006), these data provide
a mechanistic link between Ire1-Xbp1 silencing in MM cells and
PI insensitivity.
To determine if BTZ-refractory MM tumors in the clinic show
evidence of plasma cell de-commitment or maturation arrest,
we next examined the gene expression of tumor samples from
patients with MM in whom either a CR or PD developed
following treatment with BTZ (Figure 5F). We compared the
differential gene expression of the two tumor groups with pro-
grammed changes in gene expression seen during the differen-
tiation of B cells to plasma cells (Figure 5G; Table S1; Jourdan
et al., 2011). Gene sets defining expression differences between
CD20+ memory B cells, activated CD20low CD38 B cells,
CD20 CD38 pre-plasmablasts, CD20 CD38+ CD138 plas-Camablasts, and plasma cells were derived using the expression
profile of mature plasma cells as a common denominator.
Notably, by GSEA, expression of plasma cell maturation genes
was significantly enriched in BTZ-responsive tumors (q = 0.03,
NES +1.5) and reduced in BTZ-resistant tumors (q < 0.01,
NES 1.5), suggesting that while BTZ-responsive tumors
contain a high proportion of mature plasma cells, BTZ-resistant
MM tumors may contain greater proportions of less differenti-
ated cells.
Included in the leading edge of differentiation genes whose
expression was diminished in BTZ-resistant primary MM were
FRZB, WNT5A, IL6R, CD38, EDEM1, and EDEM3 (Figure 5F;
red bar), which are all expressed at higher levels in plasma
cells than in activated B cells or pre-plasmablasts (Figure 5G);
their relative underexpression in BTZ-refractory MM therefore
supports the presence of maturation arrest in PI-resistant
primary tumors. Conversely, genes that appeared to be upre-
gulated in BTZ-resistant MM tumors included the chemokine
ligands CCL3 and CCL4, CD86, MYC, BACH2, and WNT3,
which are expressed at higher levels in activated B cells
and pre-plasmablasts than in plasma cells (Figure 5F), sug-
gesting that BTZ-refractory primary MM may be associated
with increases in these progenitor subpopulations. Additional
gene expression analyses of B cell maturation support the
presence of a ‘‘sweet spot’’ maturation stage intermediate
between B cells and plasma cells that may be intrinsically
less susceptible to PI-induced cytotoxic ER stress (Figures
S5D and S5E).
Xbp1s– B Cell Progenitors in MM
Our observations that Ire1-Xbp1 suppression correlates with
BTZ resistance in MM and that B cell and pre-plasmablast
gene set expression is increased in BTZ-refractory MM,
lead us to examine primary MM tumors for the existence of
Xbp1s progenitor populations. Using FACS, viable plasma
cells and B-lineage cells were isolated from patient bone
marrows and then segregated according to CD38/CD138
status (Figures 6A and 6B). Tumor cells within these subpopu-
lations were identified by the presence of tumor clone FISH
abnormalities, and were further characterized for Xbp1s and
CD20 expression by immunoflourescence-flourescent in situ
hybridization (IF-FISH) (Figures 6C and S6). Using this tech-
nique we isolated five subpopulations of MM tumor cells from
primary MM samples, including CD20+ CD38 CD138 Xbp1s
B cells, CD20low CD38 CD138 Xbp1s activated B cells,
CD20 CD38 CD138 Xbp1s pre-plasmablasts, CD38+
CD138low Xbp1s+ plasmablasts, and CD38+ CD138+ Xbp1s+
plasma cells. The existence of these tumor progenitor cells
was observed directly with IF-FISH and was confirmed by the
greater-than background rate of cells positive for the tumor
FISH abnormality within sorted subpopulations. Virtually all
CD38 CD138 tumor cells were Xbp1s, while the majority
of tumor B cells were CD27+ (Figure 6C), consistent with a
post-germinal center memory phenotype. In some samples,
tumor B cells accounted for the majority of bone marrow
memory B cells (not shown). Xbp1s tumor B cells and pre-
plasmablasts express lower levels of Chop than Xbp1s+ tumor
plasma cells and plasmablasts (Figure 6D), suggesting that
Xbp1s tumor progenitors, like Xbp1s-silenced MM cell lines,ncer Cell 24, 289–304, September 9, 2013 ª2013 Elsevier Inc. 297
Figure 6. Tumor Progenitor Subpopulations
in a Patient with Newly Diagnosed MM
(A) The clinical information of the patient whose
bone marrow was examined.
(B) Bone marrow MM cells were enriched by
sequential FACS for lymphoid FSC/SSC (left
panel), by removal of aggregates (second and
third panels) and by negative selection for CD2
(T and NK cells) and CD14 (monocytes). Gates are
shown in pink.
(C) Tumor cells gated into subpopulations by
CD38 and CD138 status. Single viable CD38+
CD138+ plasma cells (a), CD38+ CD138 plas-
mablasts and B cells (b), and CD38 CD138
B cells (c) were examined for concurrent Xbp1s
protein expression and for IGH-CCND1 gene
fusion (arrows) by IF-FISH on single cells. Viable
CD38 CD138 B cells from (Cc) were further
examined for concurrent CD20 and CD27
expression and for IGH-CCND1 by IF-FISH (d).
Each row illustrates a single cell. Scale bars (5 mm)
are identical for IF and FISH; monochrome insets
are shown at 0.53 scale. The overall proportion of
cells in each subpopulation with strong (+), weak
(w), or no () expression of Xbp1s and the
proportion of cells positive (+) for IGH-CCND1,
compared with the background rate (bg), are
quantified and shown in the bar graphs. Error bars
represent SEM (n > 100).
(D) Ddit3 (Chop) protein expression in primary MM
tumor progenitors. Progenitor stages (left to right)
were characterized by CD20, Xbp1s, and Chop
IF-FISH. Each column illustrates single cells. Scale
is consistent across micrographs. The mean Chop
IF score by MM progenitor stage is quantified and
shown in the bar graph.
See also Figure S6.
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Xbp1s Progenitors Mediate PI Resistance in MMhave lower basal ER stress than tumor cells that have under-
gone plasma cell maturation.
Xbp1s– MM B Cell and Pre-Plasmablast Progenitors
Survive Therapeutic BTZ and Are Enriched in
BTZ-Refractory MM
In newly diagnosed MM and in patients relapsing following treat-
ment discontinuation, the predominating tumor cells are Xbp1s+
plasma cells or plasmablasts (Figures 6, 7A, and 7D), although
progenitor subpopulations including CD20 CD38 CD138
Xbp1s pre-plasmablasts and CD20low CD38CD138 Xbp1s
activated B cells were consistently identified (Figures 6Cd and
7Af). Progenitor CD20+ CD38 CD138 Xbp1s B cells with298 Cancer Cell 24, 289–304, September 9, 2013 ª2013 Elsevier Inc.strong CD20 staining were identified in
nearly all samples but were compara-
tively rare.
Supporting our conclusion that MM
tumor cells with arrested secretory
maturation are BTZ resistant, in some
primary MM tumors with PD on BTZ
therapy (Figure 7B), substantial expan-
sion of tumor CD20low CD38 CD138
Xbp1s activated B cell and CD20
Xbp1s pre-plasmablast subpopulations
was observed, causing activated CD20low B cells or CD20
pre-plasmablasts to become the predominant subpopulations
in these tumors (Figures 7Be, 7Bf, and 7D). The marked expan-
sion of these subpopulations in patients progressing on PI
therapy is consistent both with a partial tumor maturation arrest
and with relative invulnerability of these progenitor stages to
BTZ. CD20+ B cell progenitors were also detectable in these
tumors and appeared viable and enriched despite BTZ-therapy
(Figures 7Bf lower panels and 7D). In contrast, plasmablasts
and plasma cells were reduced; their numbers, 7-AAD staining,
and appearance (Figures 7Bb–d and 7D) suggested continued
susceptibility of these more mature subpopulations to BTZ
therapy.
Figure 7. Tumor Progenitor Subpopulations in Relapsed or Refractory MM
(A) Findings from a patient with relapsed MM following BTZ discontinuation. (a) The clinical information of the patient whose bone marrow was examined. (b)
Patient bone marrow was FACS sorted as in Figure 6. Viable CD38+ CD138+ plasma cells (c), CD38+ CD138/low plasmablasts (d), and CD38 CD138 cells (e)
were examined for the presence of Xbp1s by IF and for the loss of chromosome 1p32 (arrows), which contains the CDKN2C locus, by FISH. (f) Viable CD38
CD138 B cells were also examined for CD20 expression and for chromosome 1p32 loss by IF-FISH.
(B) Findings from a patient withMMwith progression on BTZ therapy. (a) The clinical information of the patient. (b) The patient’s bonemarrowwas FACS sorted as
in Figure 6. Viable CD38+ CD138+ plasma cells (c), CD38+ CD138/low plasmablasts (d), and CD38CD138 cells (e) were examined for the presence of Xbp1s by
IF and for trisomy of chromosome 11, which contains the CCND1 locus (arrows), by FISH. (f) Viable CD38 CD138 B cells were also examined for CD20
expression and for gain of CCND1 by IF-FISH.
(C) Findings from a patient with MM following intensive BTZ and DPACE chemotherapy with clinical response. (a) The clinical information of the patient. (b) The
patient’s bone marrow was FACS sorted as in Figure 6. Viable CD38+ CD138+ plasma cells were not identified. Viable CD38+ CD138/low plasmablasts (c), and
(legend continued on next page)
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Cancer Cell
Xbp1s Progenitors Mediate PI Resistance in MMBecause MM is incurable in the vast majority of patients even
with intensive multiagent therapy, we evaluated the minimal re-
sidual disease in patients treated with BTZ-based therapy. Fig-
ure 7C shows a representative marrow sample obtained 3 weeks
after sequential BTZ-based treatment (CyBorD) and DPACE
chemotherapy. This sample shows an almost empty marrow
with delayed recovery of normal marrow elements post-chemo-
therapy. At this sampling, no viable MM plasma cells could be
detected by flow. However, small residual populations of tumor
cells were identified, with phenotypes compatible with activated
CD20low B cells, pre-plasmablasts and early CD138 Xbp1slow
plasmablasts. Because Xbp1s cells preferentially survive BTZ
(Figure 1), the presence of CD138Xbp1slow tumor plasmablasts
in this marrow may reflect differentiation from earlier progenitors
in the post treatment interval.
In each of the MM patient bone marrow samples examined in
Figure 7, the proportion of CD38CD138CD20+ B cells, CD38
CD138 CD20low activated B cells, and CD38 CD138 CD20
pre-plasmablasts that showed tumor-specific clonal FISH
abnormalities, such as loss of chromosome 1p32, gain of
CCND1 or fusion of IGH-CCND1 genes, consistently exceeded
the background FISH positive rate, confirming the presence of
tumor progenitor cells within these isolated subpopulations, as
in Figure 6. Similar tumor progenitor subpopulations were also
identified in hyperdiploid MM and in MM tumors bearing t(4;14)
IGH-FGFR3 gene rearrangement (Figure 8A), demonstrating
that MM B cell and pre-plasmablast progenitors exist across a
broad spectrum of MM genetic subtypes. Overall, our examina-
tion of primary MM tumors at various treatment stages suggests
that persistence of tumor progenitor subpopulations accounts
for the failure to cure MM with PI-based treatment strategies,
even when complete response may be attained within the
plasma cell compartment.
DISCUSSION
Although PIs can substantially debulk MM, these drugs fail to
cure patients. We show here that primary MM tumors consist
not only of Xbp1s+ plasma cells and plasmablasts, but also of
subpopulations of Xbp1s pre-plasmablasts and of earlier
CD20+ B cell progenitors (Figure 8A) that are intrinsically PI
insensitive. Whereas BTZ is potently cytotoxic to the predomi-
nating MM plasma cell and plasmablast compartments, tumor
progenitor subpopulations including Xbp1s pre-plasmablasts
and B cells persist in BTZ-treated patients (Figure 8B). We pro-
pose that the inability of PIs such as BTZ to address these non-
secretory tumor cell progenitors substantially accounts for the
failure of PI therapy to cure MM.
The malignant plasma cells encountered in MM are profes-
sional secretory cells typified by massive protein synthesis, an
expanded ER network, and elevated basal ER stress. This likely
explains the unique sensitivity of MM to PIs, which exacerbate
ER stress by inhibiting ERAD (Elkabetz et al., 2004; Lee et al.,
2003; Obeng et al., 2006). Xbp1s progenitors however lackCD38 CD138 B cells (d) were examined for concurrent Xbp1s protein express
CD138 B cells were also examined for CD20 expression and for IGH-CCND1 b
(D) MM tumor progenitor frequency summarized by patient status for the bone m
Scale bar: 5 mM. See also Figure S7.
300 Cancer Cell 24, 289–304, September 9, 2013 ª2013 Elsevier Incfull secretory status and produce less Ig (Jourdan et al., 2011;
Reimold et al., 2001). XBP1-silenced MM plasma cells similarly
produce less Ig. Because the foremost activity of the ER in
plasma cells is Ig synthesis, pre-plasmablasts and earlier pro-
genitors, which produce less Ig, have a lower ER pre-load than
plasma cells, rendering them predictably less vulnerable to lethal
ER stress when ERAD is inhibited.
The finding that suppression of a branch of the ER homeo-
static UPR mediates PI resistance, when PIs induce cyto-
toxicity in MM via the induction of ER stress, is notably contrary
to any expectation from consideration of the UPR alone. How-
ever, whereas PIs cause activation of Atf6 and Perk in
response to ER stress, Xbp1s activity is only minimally
enhanced, perhaps because PIs stabilize ubiquitinated Xbp1u,
which can act as a dominant negative (Davenport et al., 2007;
Lee et al., 2003; Obeng et al., 2006). Because Xbp1 fails to
contribute to ER homeostasis following PI treatment, its loss
likely has no negative effect on the survival of PI-treated cells.
Instead, the overriding effect for MM cells of Xbp1 suppression
is a de-commitment to secretory Ig production, which reduces
ER loading and ultimately enables the cell to better withstand
ERAD inhibition.
Notably the existence of PI-insensitive Xbp1s tumor progen-
itors within primary MM tumors likely produces class-effect PI
resistance that is independent of drug identity, in contrast to
resistance produced by PI-binding site PSMB5 mutations.
Therefore, primary MM tumors that are resistant to BTZ via
Xbp1s tumor progenitors may also prove to be cross-resistant
to proteasome inhibition induced by carfilzomib, the second-
in-class PI recently approved by the US Food and Drug Admin-
istration, consistent with early clinical findings (Siegel et al.,
2012).
Xbp1 has been reported to be essential for MM pathogenesis
(Carrasco et al., 2007). Because Ire1 directly regulates Xbp1, Ire1
inhibitors are currently under development for the treatment of
MM (Koong et al., 2006; Kotz, 2011; Papandreou et al., 2011).
However, we find that Xbp1 is not required for MM tumor cell
survival, only for secretory maturation, and that its absence pro-
motes PI resistance. This suggests that Ire1 inhibitors used
outside of carefully construed combination strategies could
prove ineffectual for the treatment of MMandmay be deleterious
if combined with PIs.
Maturation arrest likely represents a final common pathway
that unifies a spectrum of genetic or epigenetic changes within
MM tumors that escape therapeutic pressures or the limitations
of the microenvironment. Notably, PRDM1, like XBP1, is essen-
tial for plasma cell maturation and for Ig production (Shapiro-
Shelef et al., 2003) and is also recurrently mutated in MM tumors
(Chapman et al., 2011), suggesting that mutation of genes other
than IRE1 or XBP1 may drive maturation arrest in MM. Further-
more, mutations of IRE1 and XBP1 can be identified in MM cell
lines that have not been exposed to BTZ (data not shown), sug-
gesting that such mutations can serve purposes other than BTZ




Figure 8. Tumor Progenitor Cells inMultiple
Myeloma and Their Role in Therapeutic
Resistance
(A) Summary of primary MM progenitor stages,
which correspond to physiological stages of B cell
to plasma cell maturation (from left to right), as
observed in MM genetic subtypes with t(11;14)
IGH-CCND1 (top), t(4;14) IGH-FGFR3/MMSET
(middle), or hyperdiploid karyotype (bottom).
Progenitors were characterized by IF-FISH as in
Figure 6. CD20 protein expression is shown in
yellow; Xbp1s protein is shown in pink. Gene
fusions between IGH (top and middle, green) and
CCND1 (top, red) or FGFR3 loci (middle, red) are
indicated by a yellow arrow. In the bottom row,
trisomies of chromosomes 5 (green) and 9 (blue)
and diploidy of chromosome 15 (red) are indicated
by arrows. Scale bars: 5 mm.
(B) Schema showing tumor progenitor organiza-
tion in newly diagnosed MM (top). Tumor B cell
and pre-plasmablast progenitors are intrinsically
resistant to PI, preventing cure, even in patients
who achieve plasma cell complete response
(CR; middle). MM progression on PI treatment is
achieved in someMM tumors by maturation arrest
at the pre-plasmablast or earlier B cell stages,
preventing secretory commitment. Mutations
identified in MM that may mediate maturation
arrest are shown in red (bottom). Cells eliminated
by PI therapy are shown as ghosts.
(C) Schema comparing the relative ER capacity
and ER burden of plasma cell precursors. A
‘‘sweet spot’’ appears to exist at the activated B
cell and pre-plasmablast stage, where ER matu-
ration precedes secretory Ig production, contrib-
uting to the reduced susceptibility of these cells
to lethal ER stress following PI-induced ERAD
inhibition. Whereas some MM tumors develop PI
resistance by maturation arrest at the pre-
plasmablast stage, mantle cell lymphoma is
instead reported to achieve PI resistance by
promoting maturation toward this state.
(D) A model of intratumor cellular diversity, which
likely contributes to the failure to cure MM. A
plethora of tumor cell phenotypes arise from the
presence of multiple genetic subclones and from
multiple maturation stages within each subclone.
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Xbp1s Progenitors Mediate PI Resistance in MMsuggests that these tumors have reduced IL-6 sensitivity (with
reduced IL6R and IL6ST), which can be directly attributed to
suppression of Xbp1s. This suggests that MM maturation arrest
not only enables PI resistance, but may also facilitate cytokine
independence and extra-medullary growth. In addition, matura-
tion arrest in MM likely contributes to the emergence of
oligosecretory disease. Therefore, PIs appear to exert a selec-
tive pressure on MM tumors that may alter the clinical picture
of relapsed MM encountered by modern physicians, contrib-
uting to a higher incidence of extra-medullary oligosecretory
disease.
While we demonstrate that MM cells achieve BTZ resistance
via de-commitment to terminal plasma cell maturation, others
have instead found that MCL tumor cells attain BTZ resistance
by plasmacytic differentiation (Pe´rez-Gala´n et al., 2011). How-
ever, BTZ-resistant MCLs fail to acquire Xbp1s or Ig secretion,
indicating that such cells are not full-fledged plasma cells and
suggesting that their differentiation state resembles that of
BTZ-resistant MM cells, namely activated B cells or pre-plasma-
blasts. We propose that a maturation ‘‘sweet spot’’ exists
between pre-germinal center B cells and plasma cells, exempli-
fied by cells with low ER burden that are intrinsically less suscep-
tible to the lethal effects of PI, because such cells express the
machinery of the adaptive UPR, but have not yet committed to
Ig production (Figure 8C).
The role of tumor progenitors and maturation arrest in
therapeutic resistance described here may be illustrative for
other drugs and cancers, particularly for therapies targeted
toward distinctive characteristics of well-differentiated tissues
such as secretion, hormone responsiveness, or antigen ex-
pression. Such treatments, like PIs, may fail to address less
distinctive progenitor populations and may thereby fail to
provide cure.
The biology of MM is shown to be related to that of other
B cell non-Hodgkin lymphomas in demonstrating a discernible
trail of tumor cell maturation from B cells. Whereas most MM
contain multiple genetic subclones that respond to treatment
in ‘‘clonal tides’’ (Keats et al., 2012), we propose that within
each subclone there exists a spectrum of progenitors that
markedly contribute to intratumor diversity and to the ability of
MM tumors to endure treatment (Figure 8D). Because tumor
progenitors contribute to treatment failure in MM, these sub-
populations must be addressed by future therapeutic strategies
to produce a pervasive cure for patients.
EXPERIMENTAL PROCEDURES
RNAi Screens
High-throughput siRNA studies in MM cells were conducted as described
(Tiedemann et al., 2010, 2012; Zhu et al., 2011). To identify BTZ resistance
mechanisms, genes were ranked by mean siRNA Bliss independence scores
at BTZ IC90.
Gene Expression Data
MM tumor profiles from patients enrolled on the APEX Study 039 of BTZ were
obtained from NCBI Gene Expression Omnibus (GEO; GSE9782; Mulligan
et al., 2007). Three Xbp1 signature gene sets were used: XBP1_Staudt_SigDB
reflects Xbp1 overexpression in B cells (Shaffer et al., 2006) and together with
other lymphoid transcription factor signatures was obtained from http://
lymphochip.nih.gov/signaturedb/; V$XBP1_01 represents genes with pro-
moters containing a conserved Xbp1 motif and is from the Broad MSigDB at302 Cancer Cell 24, 289–304, September 9, 2013 ª2013 Elsevier Inchttp://www.broadinstitute.org/gsea/msigdb/index.jsp; XBP1_MM and the
related Ire1 signature, IRE1_MM, were generated by shRNA knockdown of
Xbp1 or Ire1 in MM cells. Plasma cell progenitor profiles were obtained from
ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/; E-MEXP-3034 and
E-MEXP-2360; Jourdan et al., 2011).
Lentiviral Transductions
Viruses were prepared in 293T cells. MM cells were transduced using 293T
supernatant diluted to 30%–50% in media and 8 mg/ml polybrene.
XBP1 Constructs
Human XBP1u and XBP1s cDNA (OriGene) were cloned into pWPIs1. Muta-
tions were generated with PCR.
Gene Expression Profiling
Samples were hybridized on Affymetrix HG-U133 Plus 2.0 GeneChip
microarrays (Affymetrix) and analyzed using GeneSpring GX 12.1 (Agilent
Technologies).
MM Samples
All patient samples were obtained following informed consent in compliance
with the Declaration of Helsinki and a protocol approved by the University
Health Network Research Ethics Board.
IF-FISH
Slides were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton
X-100, incubated with primary and secondary antibodies and then mounted
in Vectashield (Vector Laboratories). IF images were acquired. Coverslips
were removed and cells were treated with 0.005% pepsin in 0.01N HCl, 1%
formaldehyde, and with ethanol and were then hybridized with Vysis LSI or
Cytocell Aquarius DNA Probes. FISH images were acquired at IF image
coordinates.
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